| December 5, 2012 |
December 5, 2012
Vical Licenses Vaxfectin(R) Adjuvant to Cyvax for Use in Malaria Vaccines
|
| November 12, 2012 |
November 12, 2012
Vical to Present at Credit Suisse 2012 Healthcare Conference
|
| November 8, 2012 |
November 8, 2012
Preclinical Data Support Potential Combinations for Allovectin(R) With Emerging Immunotherapies
|
| November 7, 2012 |
November 7, 2012
Vical Reports Third Quarter 2012 Financial Results and Progress in Key Development Programs
|
| November 2, 2012 |
November 2, 2012
Vical Names Mammen P. Mammen, Jr., M.D., Vice President, Clinical Vaccines
|
| October 31, 2012 |
October 31, 2012
Vical Announces News Release and Conference Call Schedule for Third Quarter 2012 Financial Results
|
| October 16, 2012 |
October 16, 2012
Vical Appoints George J. Morrow to Board of Directors
|
| September 27, 2012 |
September 27, 2012
Vical to Present at 3rd Annual Cancer Immunotherapy Conference
|
| September 13, 2012 |
September 13, 2012
Vical Licenses DNA Immunization Technology and Vaxfectin(R) Adjuvant to Bristol-Myers Squibb for Use in Antibody Production
|
| August 29, 2012 |
August 29, 2012
Vical to Present at September Investor Conferences
|
| August 6, 2012 |
August 6, 2012
Vical to Present at Canaccord Genuity Annual Growth Conference
|
| August 1, 2012 |
August 1, 2012
Vical Reports Second Quarter 2012 Financial Results and Progress in Key Development Programs
|
| July 25, 2012 |
July 25, 2012
Vical Announces News Release and Conference Call Schedule for Second Quarter 2012 Financial Results
|
| July 5, 2012 |
July 5, 2012
Vical to Present at JMP Securities Healthcare Conference
|
| June 13, 2012 |
June 13, 2012
Vical to Present at Wells Fargo Securities Healthcare Conference
|
| May 22, 2012 |
May 22, 2012
Vical Announces Publication of Herpes Simplex Vaccine Mouse Study Data
|
| May 16, 2012 |
May 16, 2012
Vical Updates Herpes Simplex Vaccine Development at ASGCT Conference
|
| May 8, 2012 |
May 8, 2012
Vical to Present at Upcoming Investor Conferences
|
| May 2, 2012 |
May 2, 2012
Vical Reports First Quarter 2012 Financial Results and Progress in Key Development Programs
|
| April 25, 2012 |
April 25, 2012
Vical Announces News Release and Conference Call Schedule for First Quarter 2012 Financial Results
|
| April 2, 2012 |
April 2, 2012
Astellas and Vical Advance Toward Phase 3 Trial of TransVax(TM) CMV Vaccine Triggering $10 Million Milestone Payment to Vical
|
| March 28, 2012 |
March 28, 2012
Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Vaxfectin(R) Adjuvant
|
| March 5, 2012 |
March 5, 2012
U.S. Navy Advances Dengue DNA Vaccine Using Vical's Vaxfectin(R) Adjuvant
|
| February 29, 2012 |
February 29, 2012
Vical to Present at Upcoming Investor Conferences
|
| February 13, 2012 |
February 13, 2012
Vical to Present at Upcoming Investor Conferences
|
| February 8, 2012 |
February 8, 2012
Vical Reports 2011 Financial Results and Progress in Key Development Programs
|
| February 2, 2012 |
February 2, 2012
Vical Announces News Release and Conference Call Schedule for 2011 Financial Results
|
| January 30, 2012 |
January 30, 2012
Vical Presents Case Study on Successful Design of Allovectin(R) Phase 3 Melanoma Trial
|
| January 11, 2012 |
January 11, 2012
Vical Provides Updates on CMV Vaccine Programs
|
| January 10, 2012 |
January 10, 2012
Vical to Present at Noble Financial Capital Markets Conference
|
| January 6, 2012 |
January 6, 2012
Vical Incorporated Prices Public Offering of Common Stock
|
| January 5, 2012 |
January 5, 2012
Vical Incorporated Announces Proposed Public Offering of Common Stock
|